## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -7.2% below STRENGTH zone (3.0-6.0%); PEG 1.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($649.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma**
- Source: Quiver Quantitative | 20251207T220841 | Somewhat-Bullish | Relevance: 100%
-  Regeneron Pharmaceuticals announced promising interim results from its Phase 1/2 LINKER-MM4 trial for Lynozyfic™ (linvoseltamab) in adults with newly diagnosed multiple myeloma. The trial showed that all dose groups achieved a very good partial response or better (VGPR+) of ≥70%, with a high rate of minimal residual disease negative status. Regeneron will host a virtual investor event on December 10, 2025, to discuss its multiple myeloma development program further, highlighting the drug's potential as a foundational component for frontline treatment.

**2. Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251209T122957 | Neutral | Relevance: 99%
- Ossiam reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 59.5% in Q2 2025, selling 22,234 shares and retaining 15,160 shares valued at $7.959 million. Other institutional investors also adjusted their holdings, while company insiders like VP Jason Pitofsky and Director Christine A. Poon sold significant shares. Regeneron Pharmaceuticals reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.88 per share.

**3. ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline**
- Source: Medical Marketing and Media | 20251209T161534 | Bullish | Relevance: 99%
-  Regeneron presented new early data on two of its blood cancer drugs, linvoseltamab and odronextamab, at the American Society of Hematology (ASH) annual conference. Linvoseltamab showed efficacy as a monotherapy in newly diagnosed multiple myeloma, with a 70% very good or partial response rate. Odronextamab, in a trial combining it with CHOP chemotherapy for diffuse large B-cell lymphoma, achieved a 100% complete response rate among 13 patients.

**4. RBC Capital reiterates Sector Perform rating on Regeneron stock**
- Source: Investing.com | 20251209T150836 | Somewhat-Bullish | Relevance: 99%
-  RBC Capital has reaffirmed its Sector Perform rating and $708.00 price target for Regeneron Pharmaceuticals (NASDAQ:REGN), noting recent stock appreciation due to positive developments like EyleaHD label expansion and Dupixent's continued strength. However, the firm expresses uncertainty about the differentiation of Regeneron's fianlimab against Bristol Myers Squibb's Opdualag, which could temper future stock upside. Despite this, other analysts have set higher price targets for Regeneron, reflecting varying outlooks on its pipeline and collaborations.

**5. Regeneron (REGN): Revisiting Valuation After a Short-Term Pullback and Longer-Term Shareholder Weakness**
- Source: Simply Wall Street | 20251210T023345 | Somewhat-Bullish | Relevance: 98%
-  Regeneron Pharmaceuticals (REGN) has experienced a short-term pullback despite a strong 90-day performance. The stock is considered 9.9% undervalued with a narrative fair value of approximately $768, driven by the success of EYLEA HD and anticipated regulatory approvals. Investors are evaluating whether this pullback presents a new buying opportunity or if future growth is already accounted for.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |
| 2025-11-24 | Scotiabank | $770 | $650 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |
| 2025-11-24 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($20.86M) |
| Sells | 5 ($11.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $11M sold (5 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +18%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +18%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.4B |
| Beta | 0.37 |
| 52W Range | $476.49 - $791.49 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 17.5 |
| Current P/E | 16.0 |
| YoY Growth | -8.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -5.9% to -7.2% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.2pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-10.96), momentum weakening. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -7.22% (CS: 2) | Weak |
| RSI_14 | 46.7 | Neutral |
| MACD Histogram | -10.96 | Bearish |
| vs SMA20 | 0.953x | Below |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.156x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $692.58
- **Stop Loss:** $649.50 (6.2% risk)
- **Target:** $735.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 6
- **Position Value:** $4,155.48
- **Portfolio %:** 4.16%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*